Study Links Iron Imbalance to Dry AMD, Validating PulseSight's Transferrin Therapy

AMD affects 200 million people worldwide and is the leading cause of central vision loss in the elderly, causing irreversible loss of reading ability and facial recognition.

For the 200 million people worldwide whose central vision is quietly being consumed by age-related macular degeneration, science has long struggled to name a cause worthy of the damage. Researchers in Paris have now identified iron dysregulation—not merely as a bystander, but as an active architect of retinal destruction—and found that a protein the body already makes, transferrin, can restore balance and protect the cells that make sight possible. The discovery, born from collaboration between Inserm, Cochin Hospital, and biotech firm PulseSight Therapeutics, reframes dry AMD as a disease wit

Study Links Iron Imbalance to Dry AMD, Validating PulseSight's Transferrin Therapy

Cobertura Relacionada

Recibe The Register en tu bandeja